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One of the key aspects to the good management of patients with
advanced cancer is symptom control. In recent years it has been
demonstrated that with attention to detail and good clinical prac-
tice, cancer pain can be controlled in a large proportion of patients
(Twycross, 1994). Consequently, attention has now shifted
towards the better management of other symptoms. Before
improvements can occur it is first necessary to recognize which
symptoms are most troublesome, and to devise simple methods by
which they can be assessed. This is not a trivial problem, particu-
larly when the patients concerned are severely debilitated. There
have been no controlled studies using validated measures to assess
the extent of fatigue in patients with advanced cancer who are no
longer receiving active therapy. Uncontrolled studies in this popu-
lation have reported fatigue prevalence to be anywhere between
33% and 89% (Walsh and Saunders, 1984; Coyle et al, 1990;
Dunphy and Amesbury, 1990; McCarthy, 1990; Hardy et al, 1994;
Donnelly and Walsh, 1995; Vainio and Auvinen, 1996). However,
fatigue is also a common problem in the general population (Cox
et al, 1987) and it is unclear how much of the fatigue experienced
by the patients in these studies is in excess of that experienced by
an otherwise healthy population of the same age.
The causes of cancer-related fatigue are also unknown. It is often
assumed to be related to poor nutritional status (Neuenschwander
and Bruera, 1996). Cachectic patients frequently have decreased
muscle bulk and this might be expected to lead to physical weakness
and easy fatiguability. Moreover, some authors have reported
abnormal muscle electrophysiology in cancer patients even in the
absence of cachexia (Bruera et al, 1988; Monga et al, 1997).
However no study has yet demonstrated that these changes in muscle
function are associated with increases in subjective fatigue. In the
general population fatigue is frequently associated with psycho-
logical morbidity (Pawlikowska et al, 1994; Lawrie and Pelosi,
1995) and a similar association has been found in cancer patients
receiving chemotherapy or radiotherapy (Bruera et al, 1989; Blesch
et al, 1991; Morant, 1996; Smets et al, 1996). Other putative causes
of cancer-related-fatigue include anaemia, biochemical abnormali-
ties, the severity of other symptoms and non-specific ‘stress’.
Fatigue is a difficult concept to define. We propose a simple
distinction between the symptom of fatigue (a subjective sensation
of feeling easily tired, weak or lacking in energy – which can only
be measured by self-report instruments) and physical or muscular
fatigue (a demonstrable decrement in strength over time). In this
study we report the prevalence of ‘severe subjective fatigue’
(defined as a fatigue score greater than that experienced by 95%
of an age-matched control group) in patients with advanced
cancer. The clinical correlates of this symptom have also been
investigated. In particular, the hypothesis that subjective fatigue in
cancer patients is related to poor nutritional status and decreased
muscle performance has been tested. This study represents the
first prospective controlled study of fatigue in patients with
advanced cancer who are no longer receiving active therapy
(i.e. chemotherapy or radiotherapy).
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Summary Uncontrolled studies have reported that fatigue is a common symptom among patients with advanced cancer. It is also a frequent
complaint among the general population. Simply asking cancer patients whether or not they feel fatigued does not distinguish between the
‘background’ level of this symptom in the community and any ‘excess’ arising as a result of illness. The aim of this study was to determine the
prevalence of fatigue among palliative care inpatients in comparison with a control group of age and sex-matched volunteers without cancer.
In addition, the correlates of fatigue were investigated. The prevalence of ‘severe subjective fatigue’ (defined as fatigue greater than that
experienced by 95% of the control group) was found to be 75%. Patients were malnourished, had diminished muscle function and were
suffering from a number of physical and mental symptoms. The severity of fatigue was unrelated to age, sex, diagnosis, presence or site of
metastases, anaemia, dose of opioid or steroid, any of the haematological or biochemical indices (except urea), nutritional status, voluntary
muscle function, or mood. A multivariate analysis found that fatigue severity was significantly associated with pain and dypnoea scores in the
patients, and with the symptoms of anxiety and depression in the controls. The authors conclude that subjective fatigue is both prevalent and
severe among patients with advanced cancer. The causes of this symptom remain obscure. Further work is required in order to determine if
the associations reported between fatigue and pain and between fatigue and dyspnoea are causal or coincidental.
Keywords: fatigue; asthenia; neoplasms; palliative care; quality of life
1479
British Journal of Cancer (1999) 79(9/10), 1479–1486
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0236
Received 19 May 1998
Revised 5 October 1998
Accepted 14 October 1998
Correspondence to: P Stone, Trinity Hospice, 30 Clapham Common North
Side, Clapham, London SW4 0RN, UKSUBJECTS AND METHODS
Inpatients with advanced cancer were recruited from three
palliative care units between April 1996 and January 1997.
Radiotherapy or chemotherapy within the previous 4 weeks, clini-
cally apparent confusion, poor English language skills, disability
or pain affecting the non-dominant hand or an estimated prognosis
of less than 2 weeks were all exclusion criteria. The principal
investigator visited each of the participating units weekly and
approached all patients identified as being eligible to enter the
study. In the absence of the principal investigator, due to holidays
or illness, recruitment was suspended. Thus, although the patient
group did not represent a consecutive series of eligible patients
(i.e. it was a convenience sample), there is no reason to suspect a
systematic bias in patient selection. Control subjects were age and
sex-matched volunteers without cancer. They were recruited from
the ‘League of Friends’ at the respective units and were subjected
to the same inclusion and exclusion criteria as the patients. The
protocol was approved by the relevant Scientific and Ethics
Committees.
After informed consent had been obtained, the patients were
asked to undergo a number of assessments (see below). Control
subjects undertook all of the same assessments with the exception
of the blood tests, which were omitted. The intention was to repeat
all assessments (in both patients and controls) after an interval of
at least 2 weeks. However, it should be noted that due to attrition
not all patients were in fact reassessed.
Questionnaires
The Fatigue Severity Scale (FSS) (Krupp et al, 1989) is a nine-
item scale which has previously been used to assess fatigue in a
number of medical conditions (Krupp et al, 1989; Krupp et al,
1990; Packer et al, 1991) but has not been previously validated or
used in palliative care patients. Although other fatigue scales are
available (Richardson, 1998) there is no universally accepted
assessment instrument currently available. The FSS was chosen
for this study because it is a short questionnaire (an important
consideration in suck a sick patient population) which provides a
simple unitary measure of global fatigue severity. Since the FSS
had not previously been used in palliative care patients, the
psychometric properties of the scale were reassessed as part of this
study (see Results). The FSS is shown in Figure 1.
The European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ core 30)
(Aaronson et al, 1993) is a well-validated 30-item quality of life
questionnaire specifically designed for use in cancer patients. It
has also been used in large demographic surveys of quality of life
among the general population (Klee et al, 1997; Hjermstad et al,
1998). It consists of five functional scales (physical, role, cogni-
tive, emotional and social functioning), three symptom scales
(fatigue, pain and nausea/vomiting) and a number of single items
assessing additional symptoms commonly reported by cancer
patients (dyspnoea, loss of appetite, insomnia, constipation, diar-
rhoea and financial difficulties). Subjects are asked to rate each
item on a four-point scale. Scores are then transformed onto a
0–100 scale: a higher score represents a higher (i.e. ‘better’) level
of functioning, or a higher (i.e. ‘worse’) level of symptoms.
The Hospital Anxiety and Depression Scale (HADS) (Zigmond
and Snaith, 1983) is a 14-item screening tool. It consists of
separate scales for anxiety (HADA) and depression (HADD). The
scale was developed for use amongst hospital inpatients and is
designed to minimize the biological features of these conditions. It
has been previously validated in patients with advanced cancer
(Hopwood et al, 1991). Scores on each subscale can range
between 0 (no symptoms of depression/anxiety) to 21 (numerous
and severe symptoms). When the scale is used as a screening tool
in medically sick populations a cut-off score of 11 or greater on
either subscale is taken to indicate a ‘probable case’ of anxiety or
depression (Snaith and Zigmond, 1994). One of the questions on
the depression subscale (Item 8: ‘I feel as if I am slowed down’)
may be construed as referring to fatigue and so to avoid
confounding, this item was excluded from the analysis when
correlations were sought with the FSS.
Three visual analogue scales (VAS) concerning tiredness, weak-
ness and ability to concentrate were also used. While the other
questionnaires inquired about symptoms in the previous week, the
VAS specifically concerned symptoms experienced at the time of
their completion. Each VAS was 100 mm in length and was
anchored at either end by the descriptors ‘not at all’ and
‘extremely’. Thus, higher scores represented a worse level of
symptoms.
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Choose a number from 1 to 7 that indicates your degree of agreement with the following statements where 1 indicates
strongly disagree and 7 indicates strongly agree. Please answer the questions with reference to how you have been
feeling on average over the last week.
Strongly Strongly
disagree agree
1. My motivation is lower when I am fatigued 1 2 3 4 5 6 7
2. Exercise brings on my fatigue 1 2 3 4 5 6 7
3. I am easily fatigued 1 2 3 4 5 6 7
4. Fatigue interferes with my physical functioning 1 2 3 4 5 6 7
5. Fatigue causes frequent problems for me 1 2 3 4 5 6 7
6. My fatigue prevents sustained physical functioning 1 2 3 4 5 6 7
7. Fatigue interferes with carrying out certain duties 1 2 3 4 5 6 7
and responsibilities
8. Fatigue is among my three most disabling 1 2 3 4 5 6 7
symptoms
9. Fatigue interferes with my work, family or social 1 2 3 4 5 6 7
life
Figure 1 Fatigue severity scaleTests of voluntary muscle function
Due to the nature of the study population it was not possible to
subject volunteers to the standard tests of muscle strength and
fatiguability. Many patients were confined to a bed or chair for
most of the day and thus a portable bedside measure of voluntary
muscle function had to be developed. Strength was determined
with a hand-held grip dynamometer (Takei, Japan) using the best
recording from three attempts with the non-dominant hand. Hand-
grip dynamometry has previously been shown to be a reliable
measure of voluntary muscle strength even in elderly subjects
(Greig et al, 1994). Muscle fatiguability was determined by asking
subjects to squeeze the investigator’s fingers tightly for 10 s and
then to record a measurement on the dynamometer. This process
was repeated 18 times over a 6-min period. The speed of muscle
recovery was assessed by asking subjects to register a maximal
grip on the dynamometer at 1, 5 and 10 min after cessation of
exercise. Strength was measured in Newtons (1 N = 1 kg ms–2).
The hand-grip dynamometer was periodically calibrated with free
weights in order to check that it was reading true.
Other assessments
The Body Mass Index (BMI) and the Mid Arm Muscle
Circumference (MAMC) were calculated from the subjects’ height,
weight, mid-arm circumference and triceps skinfold thickness
(measured with skinfold thickness calipers, Harpenden, UK).
Patients (but not control subjects) also provided a full blood count,
routine biochemistry and in male patients without prostate cancer;
testosterone, leutinizing hormone (LH) and sex hormone binding
globulin (SHBG). Blood specimens for these latter tests were taken
before 11 am in order to minimize the effects of diurnal variation.
Statistical methods
Median survival was calculated using the Kaplan-Meier method.
Measurement scales could typically only take a defined number of
discrete values; non-parametric methods of analysis were therefore
employed, e.g. correlation was assessed using the Spearman Rank
Correlation Coefficient (Rs) and the Mann-Whitney U-test was
used for comparing groups. The calculation of Spearman’s Rank
correlation included a correction for ties (a tie occurring when two
or more data items had the same value) (Zar, 1984a). Multiple
regression analysis (Zar, 1984b) was used to identify subsets of
factors that were independently predictive of fatigue. Analysis was
undertaken using the MINITAB program (Minitab Inc, State
College, PA, USA).
RESULTS
Description of the study population
Of 122 patients initially approached, 19 refused consent and 8
were subsequently excluded because of protocol violations. None
of the controls refused consent. Data from 95 patients and 98
control subjects were included in the final analysis. There were no
significant differences in either age or sex between the two groups.
Despite being a convenience sample the control group appeared to
be reasonably representative of the UK adult population, albeit
with a moderate excess of females (57% F; 43% M). Over 90% of
the control group were white, with 49% (48/98) being overweight
or obese and 50% (49/98) having at least one concomitant medical
problem (e.g. arthritis, chronic airflow limitation or hypertension).
The median survival of patients after entry into the study was
50 days (2–776), 71% (67/95) of patients were on strong opioids
and 67% (64/95) were taking corticosteroids. A wide variety of
tumour types were represented, with the majority suffering from
lung (n = 26), breast (n = 24) or prostate cancer (n = 13). The
majority of patients had metastatic disease with bone (48/95), liver
(18/95) and lung (9/95) being the commonest sites of spread. The
median Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of the patients was 3 (i.e. confined to bed or chair for
greater than 50% of the day).
Reliability and validity of the assessment instruments
The internal consistency of the FSS was found to be acceptable in
both patients (Cronbach’s alpha = 0.94) and controls (Cronbach’s
alpha = 0.88). Test-retest reliability of the scale was assessed by
calculating the measurement error (or within subject standard
deviation), a standard method for determining instrument relia-
bility (Bland and Altman, 1996). Among the 87 control subjects
who completed the FSS on two occasions a median of 21 days
apart, the measurement error was 4.7. The underlying structure of
the FSS was further investigated by using principal components
analysis. A single factor solution explained 76% of the variation in
fatigue scores. The item loadings of the individual questions were
all in excess of 0.67. These results suggest that the sum of the
responses to the nine items on the FSS provides an adequate
summary of a single underlying factor. Although no ‘gold stan-
dard’ assessment instrument exists with which to compare the
performance of the FSS, its validity as a measure of fatigue was
supported by the significant correlation that was found between
the FSS and the EORTC Fatigue subscale (Rs = 0.73 in patients
and 0.61 in controls, P < 0.001 in both cases).
The reliability of the voluntary muscle function tests was
checked in the 87 control subjects who completed two assess-
ments. The measurement error for the grip strength readings was
17 N. The tests of muscle fatigue showed a systematic difference
between the two assessments, with control subjects becoming
less fatigued at the second visit. This probably represented a
‘learning effect’ due to the controls being more familiar with what
was required of them when they attended for a repeat assessment.
It should be noted that no such learning effect was apparent in the
advanced cancer patients, perhaps because any improvements
due to familiarity were counterbalanced by a decline in physical
performance.
Differences between groups at the first assessment
Both patients and controls complained of at least some degree of
fatigue (Table 1), but the severity of the symptom in the patients
was much worse. The prevalence of ‘severe subjective fatigue’
(defined as a score on the FSS of greater than the 95th percentile of
controls) among palliative care inpatients was 75% (Figure 2).
Patients’ grip strength was significantly less than that of control
subjects: 201 N vs 279.5 N (P < 0.001). Patients’ muscles were
also more easily fatigued (Figure 3). After 6 min exercise the
patients’ strength had declined to 61% of the pre-exercise level,
whereas the control subjects’ strength had fallen to 68% of the
initial value. Although not large, this difference was highly signif-
icant (P < 0.001). There was no difference in the speed of recovery
of muscle strength at the end of exercise between the two groups.
Fatigue in advanced cancer 1481
British Journal of Cancer (1999) 79(9/10), 1479–1486 © Cancer Research Campaign 1999Many of the patients were undernourished. If a MAMC of
less than the 15th percentile of published normal values
(Frisancho, 1974) is taken as indicating nutritional depletion, then
39/95 (41%) of patients and only 10/98 (10%) of controls were
malnourished (P < 0.001).
As expected, patients were more symptomatic than controls.
Using the recommended cut-offs for case-detection on the HADS,
27/95 (29%) patients and 6/98 (6%) controls were ‘probable cases’
of anxiety and 33/95 (35%) patients and 1/98 (1%) controls were
‘probable cases’ of depression. There were also significant differ-
ences in all of the domains assessed by the EORTC QLQ core 30.
Routine haematological and biochemical blood tests were taken
from 88/95 (93%) of the patients. Hormonal assays were under-
taken in 21/28 (75%) of male patients without prostate cancer. The
proportion of patients with blood results outside of the normal
range is shown in Table 2. There was a high prevalence of
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Table 1 Differences between patients and controls: median values (range)
Patients Controls P value
Number 95 98
Age in years 67 (30–89) 68 (41–85) NS
Gender % female 57 62 NS
Measures of subjective fatigue (higher values indicate greater fatigue)
FSS 54 (9–63) 20 (9–51) < 0.001
EORTC fatigue scale 67 (0–100) 11 (0–56) < 0.001
VAS tired (mm) 62 (0–100) 11 (0–74) < 0.001
VAS weak (mm) 61.5 (0–100) 4 (0–52) < 0.001
VAS concentration (mm) 56 (0–97) 3 (0–50) < 0.001
Measures of muscle function (6-min grip fatigue and 10-min grip recovery are expressed as a proportion of the
initial strength)
Grip strength (N) 201 (0–495) 279.5 (147–519.5) < 0.001
6 min grip fatigue 0.61 (0–1.00) 0.68 (0.43–1.01) < 0.001
10 min grip recovery 0.94 (0.63–1.23) 0.95 (0.74–1.26) NS
Measures of nutritional status (higher values indicate better nutrition)
BMI (kg/m2) 22.4 (14.0–35.6) 25.1 (18.1–40.4) < 0.001
MAMC (cm) 21.5 (14.7–31.0) 23.4 (18.2–31.5) < 0.001
Measures of psychological distress (higher scores indicate more symptoms)
HAD-A 8 (0–21) 4 (0–17) < 0.001
HAD-D 9 (0–18) 1 (0–13) < 0.001
Functional subscales and global quality of life of EORTC QLQc30 (higher scores indicate better function)
Physical function 40 (0–100) 100 (40–100) < 0.001
Role function 17 (0–100) 100 (17–100) < 0.001
Emotional function 67 (0–100) 92 (42–100) < 0.001
Cognitive function 50 (0–100) 83 (50–100) < 0.001
Social function 30 (0–100) 100 (17–100) < 0.001
Global quality of life 33 (0–100) 83 (33–100) < 0.001
Symptom subscales of EORTC QLQc30 (higher scores indicate more severe symptoms)
Nausea and vomiting 17 (0–100) 0 (0–33) < 0.001
Pain 67 (0–100) 0 (0–83) < 0.001
Dyspnoea 67 (0–100) 0 (0–67) < 0.001
Insomnia 33 (0–100) 0 (0–100) < 0.001
Anorexia 67 (0–100) 0 (0–67) < 0.001
Constipation 33 (0–100) 0 (0–67) < 0.001
Diarrhoea 0 (0–100) 0 (0–67) < 0.001
Financial affairs 0 (0–100) 0 (0–33) < 0.001
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Figure 2 Distribution of fatigue severity scale scores Figure 3 Grip fatigue expressed as a proportion of initial grip strengthanaemia, hypogonadism and hyponatraemia (all of which may
cause fatigue). However, no association was demonstrated
between the extent of these abnormalities and the level of fatigue
experienced by the patients. The only significant association was
between fatigue severity and blood urea (Rs = 0.27, P < 0.05).
Changes occurring between the first and second
assessments (in the patients)
Of the 95 patients who completed a baseline assessment only 43
were able to complete a second assessment 2 weeks later (22
patients had died, 14 were lost to follow-up, nine were too ill to
continue, four withdrew their consent, two had since developed
weakness in the non-dominant arm and one was too confused to
complete the questionnaires). Generally, the results of the second
assessment were in keeping with the results of the baseline
measurements. The only significant changes to have occurred
were a reduction in grip strength (median change of 15 N, P <
0.01), a reduction in the MAMC (median change 0.8 cm, P < 0.01)
and an improvement in insomnia (median change 16.5, P < 0.05).
Correlates of subjective fatigue at the first assessment
Patients
There were no significant associations between fatigue severity
and age, sex, diagnosis, the presence or site of metastases or the
dose of opioid or steroid (Table 3). Although patients were
malnourished and had evidence of impaired voluntary muscle
function, there was no association between the degree of these
abnormalities and the level of their fatigue. Similarly, there were
no significant associations between the FSS and either subscale of
the HADS.
Fatigue severity was, however, significantly associated with
a number of the domains of the EORTC QLQ core 30 (physical,
role and social functioning, pain, dyspnoea, insomnia, anorexia,
constipation and global quality of life).
Controls
As in the patient group, there was no association between the FSS
and the age, sex, nutritional status or muscle function of the volun-
teers. In most respects the findings in the control group were very
similar to the findings in the patient group. The most obvious
differences between the two groups was the finding of a highly
significant association between the FSS and the HADS in the
control group but the lack of such a relationship in the patients.
This difference in correlation coefficients between the two groups
was significant (P < 0.05).
Multiple regression analyses
The correlates of subjective fatigue were also explored by using
multiple regression techniques. The FSS was taken as the depen-
dent variable. The other study data were entered into the analyses
as independent variables. Certain data was, however, excluded:
• The other measures of subjective fatigue (i.e. the EORTC
Fatigue subscale and the three VAS pertaining to fatigue) –
these were clearly not independent variables.
• The ECOG performance status, the EORTC physical, role and
social functioning subscales and the EORTC global quality of
life subscale – these variables were felt to be more likely to
represent the effects of rather than the causes of fatigue.
In the patient group (Table 4), 30% of the variance in fatigue
scores could be explained by the combination of the EORTC pain
and dyspnoea scores. In the controls, 17% of the variance in
fatigue scores could be explained by the total HADS score (minus
question 8).
DISCUSSION
In this study we were able to demonstrate that subjective and
objective fatigue can be assessed in even very sick patients with
advanced cancer. Most patients were able to complete the nine-
item FSS with little difficulty. The necessity of using a control
group was demonstrated by the fact that many of the healthy
volunteers reported at least some degree of fatigue over the
preceding week. However, by defining ‘severe subjective fatigue’
as a score greater than that experienced by 95% of an age-matched
control group, we were able to account for this ‘background’ level
of fatigue.
As well as feeling more fatigued, patients had reduced voluntary
muscle strength and a diminished ability to maintain strength with
repeated contractions. It had been uncertain whether the test of
voluntary muscle fatigue devised for this research would be sensitive
enough to detect these differences. Our results indicate that this
exercise protocol was both practical to use and was able
to discriminate between healthy volunteers and cancer patients.
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Table 2 Frequency of abnormal blood results in patients
Normal range Low Normal High
n (%) n (%) n (%)
Testosterone nmol l–1 10–30 11 (52) 10 (48) 0 (0)
LH IU l–1 2–12 2 (10) 16 (76) 3 (14)
Sodium mmol l–1 135–145 27 (31) 61 (69) 0 (0)
Potassium mmol l–1 3.5–5.0 8 (9) 77 (88) 3 (3)
Urea mmol l–1 2.5–6.4 6 (7) 41 (47) 41 (46)
Glucose mmol l–1 3.9–5.9 4 (5) 33 (42) 41 (53)
Calcium mmol l–1 2.2–2.60 3 (3) 70 (80) 15 (17)
Magnesium mmol l–1 0.65–1.05 5 (8) 51 (89) 2 (3)
Phosphate mmol l–1 0.81–1.45 7 (13) 39 (74) 7 (13)
Albumin g l–1 30–50 30 (34) 58 (66) 0 (0)
Haemoglobin g dl–1 M 13.5–17.5 54 (62) 33 (38) 0 (0)
F 11.5–15.5
Note: Not all patients had all blood tests. Blood specimens were not taken from healthy control subjects.However, despite the differences in muscle strength and fatiguability
that were demonstrated between these two groups, there was no rela-
tionship between these tests and the measures of subjective fatigue.
This suggests that the symptom of fatigue, although often chiefly
experienced as a subjective sensation of physical tiredness, is not
primarily caused by muscular weakness/fatigue. Other authors have
reported a similar poor relationship between subjective and objective
measures of fatigue in patients with chronic fatigue syndrome
(Wearden and Appleby, 1996; Lawrie et al, 1997). However, very
few studies have specifically investigated this relationship in cancer
patients (Dimeo et al, 1997; Monga et al., 1997).
Cachexia and fatigue are often thought to be closely related and
we had expected to find that the more cachectic patients would
also experience more fatigue. Bruera and coworkers (Bruera et al,
1989) failed to find any such association in patients with advanced
breast cancer, but concluded that this was probably due to their
studying a relatively well nourished group of patients. In our
study, despite a high prevalence of cachexia we were still unable to
find an association between fatigue and nutritional status. This
suggests that a clearer distinction should be made between these
two symptoms and that they probably have different aetiologies.
In the general population symptoms of fatigue are often associ-
ated with psychological morbidity (Pawlikowska et al, 1994). We
found a significant association between these two symptoms in our
control group but rather surprisingly, failed to find any such asso-
ciation in the cancer patients. This is in contrast to a number of
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Table 3 Correlation (Spearman Rank) between the FSS and other study variables
Patients Controls
Age 0.00 –0.08
Correlation with measures of muscle function
Corrected grip strength –0.16 –0.08
6-min grip fatigue –0.02 0.04
10-min grip recovery 0.09 0.00
Correlation with measures of psychological distress
HAD-A 0.16 0.40***
HADD (-Q8) 0.16 0.38***
HADT (-Q8) 0.18 0.44***
Correlation with EORTC QLQc30 subscales: functional abilities and quality of life
Physical functioning –0.43*** –0.12
Role functioning –0.42*** –0.56***
Emotional functioning –0.09 –0.04
Cognitive functioning –0.15 0.04
Social functioning –0.44*** –0.47***
Global quality of life –0.35*** –0.24*
Correlation with symptom subscales of EORTC QLQc30
Fatigue 0.71*** 0.61***
Nausea and vomiting 0.08 0.13
Pain 0.45*** 0.30**
Dyspnoea 0.50*** 0.23*
Insomnia 0.41*** 0.27**
Anorexia 0.46*** 0.30**
Constipation 0.31** 0.14
Diarrhoea 0.10 0.11
Financial difficulties 0.24 –0.01
Correlation with measures of nutritional status
BMI 0.02 0.01
MAMC –0.05 –0.04
*P < 0.05, **P < 0.01, ***P < 0.001,
Table 4 Multiple regression analysis in patients and controls
Patients Controls
Step 1 2 1
Intercept 42.1 33.7 16.7
EORTC-Dyspnoea T-value 4.0 4.5 –
Slope 0.14 0.15 –
EORTC-Pain T-value 4.4 –
Slope 0.15 –
HADT-8 T-value – – 4.4
Slope – – 0.9
R2 15 30 17
Independent variables included in analysis: all EORTC QLQc30 subscales except
physical, role and social functioning, fatigue and global quality of life; HADA,
HADD(-Q8) and HADT (-Q8); BMI, MAMC; tests of voluntary muscle function;
blood resultsother studies which have found a positive relationship between
these two constructs in patients with cancer (Bruera et al, 1989;
Morant et al, 1993; Smets et al, 1996). The discrepancy may partly
be explained by the nature of our patient sample. All of the patients
in our study had advanced disease and most had multiple physical
problems and a very short prognosis. Under these circumstances it
is possible (indeed probable) that fatigue has a different origin to
that occurring in patients with earlier stage disease or indeed in the
general population. The nature of the association between fatigue
and psychological morbidity is clearly a complex one. Fatigue
may be a cause or an effect of psychological distress or the two
symptoms may both be related to other confounding factors
(Visser and Smets, 1998).
The factors which appeared to be most associated with fatigue
in the patients were the severity of their other physical symptoms
(i.e. pain, dyspnoea, insomnia, anorexia and constipation). It could
be postulated that fatigue is a result of non-specific ‘stress’
(Aistars, 1987), and that in patients with advanced cancer physical
symptoms are a major source of such stress. If this were the case,
then measures designed to relieve these other symptoms might be
expected to incidentally improve fatigue. To test this hypothesis
we are currently undertaking a study to investigate the effect of
improved pain control upon fatigue levels.
Of all symptoms, dyspnoea appeared to be the most consistently
associated with fatigue. To a certain extent this is unfortunate,
because dyspnoea is already recognized as being a difficult
symptom to treat (Higginson and McCarthy, 1989). It is unclear
whether the relationship between these two symptoms is causal or
coincidental. Dyspnoea may lead to fatigue by limiting exercise
tolerance. Some patients, particularly those with lung cancer, may
have difficulty in distinguishing between these two symptoms
(Brown et al, 1986). It is also possible that in some patients both
fatigue and dyspnoea are caused by the same underlying process.
This is a potentially fruitful area for future research. We recom-
mend that future studies into the management of dyspnoea should
also include a validated fatigue assessment (and vice versa) so that
the relationship between these two symptoms might be further
elucidated.
The results of the multiple regression analyses indicated that a
large proportion of the variance in fatigue scores remained unac-
counted for. This could partly be a reflection of our subject popu-
lation. Although the patients had a variety of different tumour
types and varied in both age and sex, they were nearly all suffering
from severe fatigue and a large number of other physical and
mental symptoms. The magnitude of a correlation coefficient is
partly dependent upon the range over which the study variables are
measured (the wider the range, the greater the potential correla-
tion). Thus, the fact that most of our patients were clustered at one
extreme or the other on most of the assessment scales which were
used, will have resulted in the correlation coefficients being lower
than if a broader population of cancer patients had been studied.
However, the use of a more heterogenous population would have
cast doubts over the applicability of the results to any particular
patient group. As has already been indicated, it may well be that
the origins of fatigue in the early stages of cancer are significantly
different from the causes of fatigue in advanced disease.
Fatigue is a difficult symptom to study in any group of patients
but particularly in those with advanced cancer. The research
methodology described in this paper was found to be both practical
and reliable in even very sick patients and could be adopted for use
in future palliative care studies. It is hoped that recognizing the
extent and severity of this symptom in advanced cancer will be the
first step towards improving its management in the future.
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